R G Kilbourn|O W Griffith|S S Gross - JoVE Visualize

Showing results (1-10 of 180) with videos related to

Pageof 18

Sort By:

Advances in Enzyme Regulation|January 1, 1997

Design of nitric oxide synthase inhibitors and their use to reverse hypotension associated with cancer immunotherapyO W Griffith, R G Kilbourn

Proceedings of the National Academy of Sciences of the United States of America|May 1, 1990

NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxideR G Kilbourn, S S Gross, A Jubran, et al.

Biochemical and Biophysical Research Communications|November 15, 1990

Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesisR G Kilbourn, A Jubran, S S Gross, et al.

British Journal of Pharmacology|June 1, 1995

Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aortaG A Joly, K Narayanan, O W Griffith, et al.

Journal of the National Cancer Institute|July 1, 1992

Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginineR G Kilbourn, S S Gross, R F Lodato, et al.

The Cancer Journal From Scientific American|February 24, 2000

Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginineR G Kilbourn, G A Fonseca, L A Trissel, et al.

Critical Care Medicine|November 1, 1994

NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogsR G Kilbourn, D M Cromeens, F D Chelly, et al.

Journal of Applied Physiology (Bethesda, Md. : 1985)|March 1, 1994

NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogsR G Kilbourn, L B Owen-Schaub, D M Cromeens, et al.

Biochemical and Biophysical Research Communications|August 15, 1991

Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophagesS S Gross, E A Jaffe, R Levi, et al.

Biochemical and Biophysical Research Communications|April 28, 1989

NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?K Aisaka, S S Gross, O W Griffith, et al.

Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:

Pageof 18

Advances in Enzyme Regulation|January 1, 1997

Design of nitric oxide synthase inhibitors and their use to reverse hypotension associated with cancer immunotherapyO W Griffith, R G Kilbourn

Proceedings of the National Academy of Sciences of the United States of America|May 1, 1990

NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxideR G Kilbourn, S S Gross, A Jubran, et al.

Biochemical and Biophysical Research Communications|November 15, 1990

Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesisR G Kilbourn, A Jubran, S S Gross, et al.

British Journal of Pharmacology|June 1, 1995

Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aortaG A Joly, K Narayanan, O W Griffith, et al.

Journal of the National Cancer Institute|July 1, 1992

Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginineR G Kilbourn, S S Gross, R F Lodato, et al.

The Cancer Journal From Scientific American|February 24, 2000

Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginineR G Kilbourn, G A Fonseca, L A Trissel, et al.

Critical Care Medicine|November 1, 1994

NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogsR G Kilbourn, D M Cromeens, F D Chelly, et al.

Journal of Applied Physiology (Bethesda, Md. : 1985)|March 1, 1994

NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogsR G Kilbourn, L B Owen-Schaub, D M Cromeens, et al.

Biochemical and Biophysical Research Communications|August 15, 1991

Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophagesS S Gross, E A Jaffe, R Levi, et al.

Biochemical and Biophysical Research Communications|April 28, 1989

NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?K Aisaka, S S Gross, O W Griffith, et al.

Pageof 18